Gilenya, Novartis' (NVS +1.9%) pill for MS, fails for the second time to get backing from the...

|About: Novartis AG (NVS)|By:, SA News Editor

Gilenya, Novartis' (NVS +1.9%) pill for MS, fails for the second time to get backing from the U.K.'s health-cost agency. It's a blow for Novartis, which hopes to turn the drug into a multi-billion dollar blockbuster that will fuel sales growth as other patents start to expire.